Skip to content

Effect of halotherapy on postoperative pulmonary complications in patients undergoing cardiac surgery : A randomized controlled trial

Clinical study on the effectiveness of preoperative ultrasonic halotherapy in preventing postoperative pulmonary complications in patients undergoing elective cardiac surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600116038
Enrollment
Unknown
Registered
2026-01-05
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative pulmonary complications

Interventions

Control group:Standardized perioperative management plan according to the ERAS guidelines for cardiac surgery: ( 3 ) All enrolled patients were provided with standardized perioperative management plan
Intervention group:The specific operation is as follows : Using instrument of halotherapy ( Nanjing Kuancheng Technology Co., Ltd., Suji Zhunzhun 20222091587, US-F100 type ). The patients in the inter

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1)Scheduled for elective cardiac and major vascular surgery; 2)Aged 18 to 80 years, inclusive; 3)Cognitively normal and able to comply with the trial procedures; 4)Provided written informed consent for participation in the study.

Exclusion criteria

Exclusion criteria: 1) uncontrolled unstable angina pectoris; 2) concomitant aortic dissection; 3) preoperative mechanical circulatory support (extracorporeal membrane oxygenation, intra-aortic balloon pump, ventricular assist device); 4) recent facial, oral, or cranial surgery or trauma; 5) active hemoptysis; 6) severe uncontrolled arrhythmia causing symptomatic or hemodynamic disturbance; 7) comorbid severe physical diseases with uncorrected clinical conditions (e.g., severe anemia, electrolyte disturbances, liver and kidney failure, and hyperthyroidism); 8) participants participating in other interventional clinical trials; 9) patients who are uncooperative or unable to communicate; 10) predicted survival of less than 6 months.

Design outcomes

Primary

MeasureTime frame
Incidence of postoperative pulmonary complications (assessed by the JAMA score) prior to hospital discharge.;

Secondary

MeasureTime frame
Forced vital capacity, FVC;Forced expiratory volume in 1s, FEV1;Maximal inspiratory pressure, MIP;Maximal expiratory pressure, MIP;Borg's perceived exertion scales;6minute walking distance, 6MWD;Hospital Anxiety and Depression Scale ( HADS ) score.;Satisfaction degree of participants;EuroQol five-dimensional questionnaire(EQ-5D) score;Kansas city cardiomyopathy questionnaire(KCCQ) score;ICU length of stay;The duration of mechanical ventilation;Duration of noninvasive ventilation(NIV);Hospital length of stay;

Countries

China

Contacts

Public ContactPengming Yu

West China Hospital of Sichuan University

13438201451@126.com+86 134 3820 1451

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026